This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Mti Biotech, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Kevin Moore - Innovator in Mitochondrial Targeting
Introduction
Kevin Moore is a notable inventor based in Ames, IA (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel compounds aimed at improving therapeutic outcomes.
Latest Patents
Kevin holds a patent for "Triphenylphosphonium-tethered salicylamine derivatives." This innovative patent focuses on creating salicylamine derivatives that are specifically targeted to the mitochondria. The goal of this invention is to enhance effectiveness and reduce the required dosages in treating conditions caused by inflammation or oxidative stress.
Career Highlights
Kevin is currently associated with Mti Biotech, Inc., where he applies his expertise in biotechnology to advance research and development. His work is pivotal in the ongoing efforts to create more effective treatments for various health conditions.
Collaborations
Kevin collaborates with esteemed colleagues, including Michael P. Murphy and Naji Abumrad. Their combined efforts contribute to the innovative research environment at Mti Biotech, Inc.
Conclusion
Kevin Moore's work exemplifies the impact of targeted therapies in biotechnology. His innovative approach to mitochondrial targeting holds promise for improving treatment efficacy in various medical conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile